IV rigosertib: Additional Phase III data

Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa.
SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan
Product: IV rigosertib ( Estybon, SyB L-1101)) ( ON 01910.Na)
Business: Cancer
Molecular target: Phosphoinositide

Read the full 283 word article

How to gain access

Continue reading with a
two-week free trial.